1. Home
  2. LGCY vs RFL Comparison

LGCY vs RFL Comparison

Compare LGCY & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGCY
  • RFL
  • Stock Information
  • Founded
  • LGCY 2009
  • RFL 2017
  • Country
  • LGCY United States
  • RFL United States
  • Employees
  • LGCY N/A
  • RFL N/A
  • Industry
  • LGCY
  • RFL Real Estate
  • Sector
  • LGCY
  • RFL Finance
  • Exchange
  • LGCY NYSE
  • RFL Nasdaq
  • Market Cap
  • LGCY 52.9M
  • RFL 48.4M
  • IPO Year
  • LGCY 2024
  • RFL N/A
  • Fundamental
  • Price
  • LGCY $5.95
  • RFL $1.96
  • Analyst Decision
  • LGCY
  • RFL
  • Analyst Count
  • LGCY 0
  • RFL 0
  • Target Price
  • LGCY N/A
  • RFL N/A
  • AVG Volume (30 Days)
  • LGCY 152.5K
  • RFL 75.0K
  • Earning Date
  • LGCY 10-07-2024
  • RFL 12-12-2024
  • Dividend Yield
  • LGCY N/A
  • RFL N/A
  • EPS Growth
  • LGCY 89.29
  • RFL N/A
  • EPS
  • LGCY 0.53
  • RFL N/A
  • Revenue
  • LGCY $46,000,316.00
  • RFL $540,000.00
  • Revenue This Year
  • LGCY N/A
  • RFL N/A
  • Revenue Next Year
  • LGCY N/A
  • RFL N/A
  • P/E Ratio
  • LGCY $10.98
  • RFL N/A
  • Revenue Growth
  • LGCY 29.74
  • RFL 92.86
  • 52 Week Low
  • LGCY $3.60
  • RFL $1.29
  • 52 Week High
  • LGCY $6.27
  • RFL $2.50
  • Technical
  • Relative Strength Index (RSI)
  • LGCY N/A
  • RFL 50.66
  • Support Level
  • LGCY N/A
  • RFL $2.00
  • Resistance Level
  • LGCY N/A
  • RFL $2.50
  • Average True Range (ATR)
  • LGCY 0.00
  • RFL 0.11
  • MACD
  • LGCY 0.00
  • RFL -0.02
  • Stochastic Oscillator
  • LGCY 0.00
  • RFL 15.63

About LGCY LEGACY EDUCATION INC

Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc, through its subsidiaries, is a clinical stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company is a significant investor in two clinical stage oncology companies, Cornerstone Pharmaceuticals, Inc., and LipoMedix Pharmaceuticals Ltd.

Share on Social Networks: